Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2022-01-06 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe
Regulatory Filings Classification · 100% confidence The document is a press release dated January 6, 2022, announcing that Pharming Group N.V. received a positive decision from the European Medicines Agency (EMA) regarding its Paediatric Investigation Plan (PIP) for the drug leniolisib. This type of announcement, detailing a specific regulatory milestone (EMA decision on a PIP) that paves the way for future marketing authorization, is a general corporate update related to regulatory progress. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a formal filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since it is a specific regulatory/clinical update that doesn't fit the more specific categories like 'LTR' (Legal Proceedings) or 'CAP' (Financing), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for miscellaneous regulatory announcements not covered elsewhere, or potentially 'LTR' if viewed as a regulatory action, but RNS is more appropriate for general positive regulatory news flow. Given the options, RNS is the most suitable general regulatory announcement code.
2022-01-06 English
6-K
Regulatory Filings
2022-01-04 English
Pharming Group and Sanofi renew strategic manufacturing partnership agreement
Regulatory Filings Classification · 100% confidence The document is a press release dated December 23, 2021, announcing the renewal of a strategic manufacturing partnership between Pharming Group and Sanofi. It details operational changes (canceling downstream production facility realization) and financial implications ($40 million capital investment savings). This type of announcement, which details significant business developments, strategic decisions, and operational updates, is characteristic of an Earnings Release (ER) or a general business update. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate classification for an initial announcement of significant business news, often released concurrently with or shortly after earnings periods, is Earnings Release (ER). It contains key highlights and commentary from the CEO, fitting the ER definition better than the broader Regulatory Filings (RNS). The document length (6236 chars) is substantial enough to be more than just a brief announcement of a report being published (RPA).
2021-12-23 English
Pharming Group reports financial results for the first nine months of 2021
Earnings Release Classification · 100% confidence The document explicitly states it presents the 'preliminary (unaudited) financial report for the first nine months ended September 30, 2021.' It contains detailed financial summaries, including revenues, gross profit, operating profit, and condensed consolidated financial statements (Profit/Loss, Balance Sheet, Cash Flow) for a period shorter than a year (nine months). This structure and content strongly indicate an Interim/Quarterly Report. Although it is a press release format, the core content is the comprehensive financial report for the nine-month period, making 'Interim / Quarterly Report' (IR) the most appropriate classification over a simple 'Earnings Release' (ER) or 'Report Publication Announcement' (RPA), especially given its length (over 25,000 characters) which suggests more than just a brief announcement. 9M 2021
2021-10-28 English
6-K Filing
Regulatory Filings
2021-10-28 English
S-8 Filing
Regulatory Filings
2021-10-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.